Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …

Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative
option for multiple myeloma (MM). We analyzed our experience of allo-HCT in MM and …

A total of 149 patients with multiple myeloma (MM) who received allogeneic hematopoietic
stem cell transplantation (allo‐HCT) with myeloablative (MAC; n= 38) or reduced‐intensity …

Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors
has the potential for long-term disease control in a subset of high-risk patients with multiple …

Background In the novel and pre–novel agent era, high-dose therapy, followed by
autologous hematopoietic cell transplantation (AHCT), has been shown to prolong survival …

To evaluate trends in allografting from unrelated donors, we conducted a study on 196
consecutive myeloma patients transplanted between 2000 and 2009 in Italy. Twenty-eight …

Many patients with multiple myeloma (MM) eventually relapse even after allogeneic
hematopoietic cell transplantation (alloHCT) for curative intent. Over the past decade …

The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple
myeloma is controversial. We analyzed the results of 205 patients transplanted in one center …

Allogeneic stem cell transplantation (allo‐SCT) has the potential to induce long‐term
remission in multiple myeloma (MM), but the role of allo‐SCT in MM is controversial due to …

Allogeneic hematopoietic cell transplant (HCT) may improve long-term multiple myeloma
(MM) control through the graft-versus-myeloma effect. The Blood and Marrow Transplant …